期刊文献+

增温器对奥沙利铂化疗病人神经毒性致肢体疼痛的影响 被引量:6

Influence of calescence instrument on limbs pain of patients undergoing oxaliplatin chemotherapy induced by its neurotoxicity
下载PDF
导出
摘要 [目的]探讨应用输液增温器对奥沙利铂静脉化疗病人神经毒性所致肢体疼痛的影响。[方法]将64例应用奥沙利铂方案外周静脉化疗的胃肠癌病人随机分为对照组30例和实验组34例,对照组采用常规护理,实验组在常规护理的同时,加用输液增温器。观察并比较两组病人输注过程中肢体疼痛的程度。[结果]实验组止痛效果明显优于对照组(P<0.05)。[结论]奥沙利铂静脉化疗中使用输液增温器可有效减轻药物引起的肢体疼痛。 Objective:To probe into the influence of calescence instrument on limbs pain for patients undergoing oxaliplatin chemotherapy induced by neurotoxicity. Methods: A total of 64 gastrointestinal cancer patients undergoing oxaliplatin intravenous chemotherapy were randomly divided into control group (30 cases) and test group (34 cases). Patients of control group cases were given routine nursing. Besides that calescence instrument was added for test group cases. Then limbs pain of patients during transfusion between both groups were observed and compared. Results: The therapeutic effect of test group cases was remarkably better than that of control group (P〈0. 05). Conclusion: Using calescence instrument during oxaliplatin intravenous chemotherapy for patients can effectively relieve drugs induced limbs pain for them.
出处 《全科护理》 2008年第28期2540-2541,共2页 Chinese General Practice Nursing
关键词 输液增温器 奥沙利铂 肢体疼痛 外周神经毒性反应 calescence instrument oxaliplatin limbs pain peripheral nerve toxic reaction
  • 相关文献

参考文献2

二级参考文献19

  • 1胡发明.奥沙利铂的不良反应和安全性[J].国外医药合成药·生化药·制剂分册,1999,20(3):184-185.
  • 2Richard H, Wilson, Tanya Lehky, et al.Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability[J] .J Clin Oncol,2002,20(7):1767 - 1774.
  • 3Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32
  • 4Sarah Taieb, Louis Descos, Gilles Freyer, et al. Lhermitte sign and urinary retention-atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002,94(9) : 2434 - 2440.
  • 5Misset JL. Oxaliplatin in practice [ J ] . Br J Cancer, 1998, 77(Suppl 4):S4- S7.
  • 6Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin; a critical review[ J ] . Clin Cancer Res ,2000,6(4) : 1205 - 1218.
  • 7Levi F, Metzger G, Massari C, et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspeets[J]. Clin Pharmacokinet,2000,38(1) : 1 - 21.
  • 8Luo FR, Wyrick SD, Charley SG. Biotransformations of oxaliplatin in rat blood in vitro[J] .J Biochem Mol Toxicol ,1999 ,13(3-4):159- 169.
  • 9Gamelin E, LeBouil A, Boisdron-celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluomuracil in colorectal cancer patients[J]. Clin Cancer Res, 1997,3(6) :891 - 899.
  • 10Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies [ J ]. Ann Oncol, 1998,9 ( 10 ) :1053- 1071.

共引文献84

同被引文献78

引证文献6

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部